The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals

The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals: A Retrospective Study and Review With Clinical Implications

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06550271

Enrollment

Registered

2024-08-13

Start date

2023-04-25

Completion date

2023-12-15

Last updated

2024-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging

Keywords

Bioavailability, Rapamycin, Aging, Longevity, Sirolimus, Healthy aging, age-related conditions, energy improvement

Brief summary

This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).

Interventions

DRUGRapamycin

Rapamycin in 2 different dosage forms (compounded and generic)

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 120 Years

Healthy volunteers

Yes

Inclusion criteria

* Receive AgelessRx's standard Rapamycin treatment protocol * Opted to complete at least 1 blood draw at their local Quest Lab

Exclusion criteria

* Not approved for current AgelessRx standard Rapamycin treatment * History of uncontrolled disease * Unable to complete at least 1 blood draw at their local Quest Lab

Design outcomes

Primary

Measure	Time frame	Description
define the relative bioavailability ratio between compounded rapamycin and generic rapamycin	8 months	define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026